SG11201809802PA - Compositions for treating or preventing vasomotor symptoms - Google Patents

Compositions for treating or preventing vasomotor symptoms

Info

Publication number
SG11201809802PA
SG11201809802PA SG11201809802PA SG11201809802PA SG11201809802PA SG 11201809802P A SG11201809802P A SG 11201809802PA SG 11201809802P A SG11201809802P A SG 11201809802PA SG 11201809802P A SG11201809802P A SG 11201809802PA SG 11201809802P A SG11201809802P A SG 11201809802PA
Authority
SG
Singapore
Prior art keywords
international
compositions
osaka
treating
pct
Prior art date
Application number
SG11201809802PA
Inventor
Joseph M Palumbo
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of SG11201809802PA publication Critical patent/SG11201809802PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111 11111111 1 1111111111111111111111111111 11 1111 11111111 1111 11111 111111111111 1111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/217351 Al 21 December 2017 (21.12.2017) WIP0 I PCT (51) International Patent Classification: A61K 31/472 (2006.01) A61P 9/00 (2006.01) A61K 31/4725 (2006.01) (21) International Application Number: PCT/JP2017/021569 (22) International Filing Date: 12 June 2017 (12.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/349179 13 June 2016 (13.06.2016) US (71) Applicant: MITSUBISHI TANABE PHARMA COR- PORATION [JP/JP]; 3-2-10, Dosho-machi, Chuo-ku, Os- aka-shi, Osaka, 5418505 (JP). (72) Inventor: PALUMBO, Joseph M.; 525 Washington Blvd., Suite 400, Jersey City, New Jersey, 07310 (US). (74) Agent: SAMEJIMA, Mutsumi et al.; AOYAMA & PARTNERS, Umeda Hankyu Bldg. Office Tower, 8-1, Kakuda-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP). — Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) Published: ,- 1 — with international search report (Art. 21(3)) 11 ir) M IN Il ei N (54) Title: COMPOSITIONS FOR TREATING OR PREVENTING VASOMOTOR SYMPTOMS 1-1 0 (57) : The present disclosure is directed to compositions and methods for treating or preventing vasomotor symptoms such ei as hot flashes, comprising a Transient Receptor Potential Melastatin 8 (TRPM8) antagonist and administering a TRPM8 antagonist, 0 respectively.
SG11201809802PA 2016-06-13 2017-06-12 Compositions for treating or preventing vasomotor symptoms SG11201809802PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349179P 2016-06-13 2016-06-13
PCT/JP2017/021569 WO2017217351A1 (en) 2016-06-13 2017-06-12 Compositions for treating or preventing vasomotor symptoms

Publications (1)

Publication Number Publication Date
SG11201809802PA true SG11201809802PA (en) 2018-12-28

Family

ID=59101629

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809802PA SG11201809802PA (en) 2016-06-13 2017-06-12 Compositions for treating or preventing vasomotor symptoms

Country Status (17)

Country Link
US (2) US10993939B2 (en)
EP (2) EP3468557B1 (en)
JP (1) JP6943887B2 (en)
KR (2) KR20230005413A (en)
CN (4) CN113384577A (en)
AU (2) AU2017285609B2 (en)
BR (1) BR112018075403A2 (en)
CA (1) CA3022808A1 (en)
CO (1) CO2018013692A2 (en)
ES (1) ES2957232T3 (en)
IL (1) IL262664B (en)
MX (1) MX2018015399A (en)
PH (1) PH12018502618A1 (en)
RU (1) RU2768875C2 (en)
SG (1) SG11201809802PA (en)
TW (1) TWI739850B (en)
WO (1) WO2017217351A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018391882A1 (en) * 2017-12-19 2020-07-02 Mitsubishi Tanabe Pharma Corporation Compositions and methods for treating or preventing vasomotor symptoms
US20220313629A1 (en) * 2019-02-01 2022-10-06 Marshall University Research Corporation Transient potential melastatin 8 (trpm8) antagonists and related methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122156A2 (en) * 2005-05-09 2006-11-16 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
WO2009073788A1 (en) 2007-12-07 2009-06-11 Firestone Leigh H Compositions and methods for treating menopausal females
CN102325763B (en) 2008-12-18 2014-01-29 詹森药业有限公司 Sulfamides as TRPM8 modulators
WO2010103381A1 (en) 2009-03-13 2010-09-16 Glenmark Pharmaceuticals S.A. Spirocyclic piperidine derivatives as trpm 8 modulators
CN102427810A (en) 2009-05-01 2012-04-25 拉夸里亚创药株式会社 Sulfamoyl benzoic acid derivatives as trpm8 antagonists
TW201103941A (en) 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
EP2481727A1 (en) 2011-01-28 2012-08-01 Dompe S.p.A. TRPM8 receptor antagonists
PL2686302T3 (en) * 2011-03-16 2017-01-31 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds having trpm8 antagonistic activity
MY157429A (en) 2011-06-24 2016-06-15 Amgen Inc Trpm8 antagonists and their use in treatments
ME03038B (en) 2011-12-19 2018-10-20 Dompe Farm Spa Trpm8 antagonists
JP5985453B2 (en) * 2012-09-14 2016-09-06 田辺三菱製薬株式会社 Pharmaceutical composition
WO2014042238A1 (en) 2012-09-14 2014-03-20 田辺三菱製薬株式会社 Sulfonamide compound
CA2959231C (en) * 2013-10-22 2022-06-21 Edward Tak Wei Di-isopropyl-phosphinoyl-alkane (dapa) compounds as topical agents for the treatment of sensory discomfort

Also Published As

Publication number Publication date
JP6943887B2 (en) 2021-10-06
TW201803595A (en) 2018-02-01
RU2768875C2 (en) 2022-03-25
TWI739850B (en) 2021-09-21
IL262664A (en) 2018-12-31
KR20230005413A (en) 2023-01-09
AU2017285609B2 (en) 2022-08-18
CN113398124A (en) 2021-09-17
US10993939B2 (en) 2021-05-04
US20210177830A1 (en) 2021-06-17
EP3468557A1 (en) 2019-04-17
CN109310689A (en) 2019-02-05
CN114748624A (en) 2022-07-15
CO2018013692A2 (en) 2019-01-18
WO2017217351A1 (en) 2017-12-21
MX2018015399A (en) 2019-04-29
US20190142821A1 (en) 2019-05-16
BR112018075403A2 (en) 2019-03-19
EP3468557B1 (en) 2023-07-26
ES2957232T3 (en) 2024-01-15
CN113384577A (en) 2021-09-14
KR20190017800A (en) 2019-02-20
RU2019100424A3 (en) 2020-09-24
IL262664B (en) 2021-10-31
AU2017285609A1 (en) 2019-01-03
RU2019100424A (en) 2020-07-15
JP2019517573A (en) 2019-06-24
EP4140484A1 (en) 2023-03-01
CA3022808A1 (en) 2017-12-21
PH12018502618A1 (en) 2019-10-07
AU2022211877A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
SG11201909949XA (en) Targeted immunotolerance
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907023UA (en) Method of reducing neutropenia
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201809751XA (en) Egfr inhibitor compounds
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201805001UA (en) Method of treating influenza a
SG11201808686VA (en) Synthesis of indazoles
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201902949PA (en) Pharmaceutical compositions and methods of treating cardiovascular diseases
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201900214UA (en) Iso-citrate dehydrogenase (idh) inhibitor